Of the 24 chemo-refractory and 30 PD-1 inhibitor refractory NSCLC, three patients had LKB1 mutations and all experienced clinical benefit. One patient had a partial response for 10 months and two patient had stable disease for 3.5 and 6.2 months, respectively. Here, STK11 is linked to non-small cell lung carcinoma.